60 Degrees Pharmaceuticals, Inc. (SXTP) Stock

Healthcare · Biotechnology · Member of Other US Stocks

60 Degrees Pharmaceuticals, Inc. (SXTP) closed at USD 0.88 on 2026-10-14, a change of -84.5 % over the past year, with a market capitalization of USD 3.16M.

60 Degrees Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

60 Degrees Pharmaceuticals, Inc. key figures

Previous close

USD 0.88 (2026-10-14)

1-year change

-84.5 %

Market cap

USD 3.16M

Enterprise value

USD 11.77M

P/E ratio (trailing)

-0.17

P/E ratio (forward)

-0.25

EPS (trailing)

-5.34

EPS (forward)

-3.58

PEG ratio

n/a

Price to book

-0.34

Revenue growth

-32.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.73

Employees

3

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for 60 Degrees Pharmaceuticals, Inc. and compare it with other stocks.